Evidence map›Paper›PMID 37291443›Full record

ArticleAAPS PharmSciTech2023

Inhaled Adjunct Therapy with Second-Line Drug Candidates for Dose Reduction in Chemotherapeutic Regimens for Multi-drug-Resistant Tuberculosis.

Sonia Verma, Nils-Jorgen K Dal, Ashish Srivastava, Reena Bharti, D V Siva Reddy, Hasham Shafi Sofi, Trisha Roy, Khushboo Verma, Sunil K Raman, Lubna Azmi and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Sonia VermaDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
Nils-Jorgen K DalDepartment of Biosciences, University of Oslo, 0316, Oslo, Norway.
Ashish SrivastavaDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
Reena BhartiDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
D V Siva ReddyDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
Hasham Shafi SofiDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
Trisha RoyDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
Khushboo VermaDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
Sunil K RamanDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
Lubna AzmiDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
Lipika RayDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
Madhav N MugaleDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India.
Amit K SinghNational JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra, 282004, UP, India.
Jyotsna SinghCSIR-Indian Institute of Toxicology, Lucknow, 226001, UP, India.
Gareth GriffithsDepartment of Biosciences, University of Oslo, 0316, Oslo, Norway. g.w.griffiths@ibv.uio.no.
Amit MisraDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India. amit_misra@cdri.res.in.ORCID http://orcid.org/0000-0001-5503-0694
Central Drug Research Institute · INUniversity of Oslo · NOIndian Institute of Toxicology Research · INNational JALMA Institute for Leprosy & Other Mycobacterial Diseases · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy of multi-drug-resistant tuberculosis (TB) requires prolonged administration of multiple drugs. We investigated whether pulmonary delivery of minute doses of drugs, along with reduced oral doses of the same agents, would affect preclinical efficacy. We prepared dry powder inhalation (DPI) formulations comprising sutezolid (SUT), the second-generation pretomanid analog TBA-354 (TBA), or a fluorinated derivative of TBA-354 (32,625) in a matrix of the biodegradable polymer poly(L-lactide). We established formulation characteristics, doses inhaled by healthy mice, and preclinical efficacy in a mouse model of TB. Oral doses of 100 mg/kg/day or DPI doses of 0.25-0.5 mg/kg/day of drugs SUT, TBA-354, or 32,625 administered over 28 days were sub-optimally effective in reducing lung and spleen burden of Mycobacterium tuberculosis (Mtb) in infected mice. The addition of 0.25-0.5 mg/kg/day of SUT, TBA-354, or 32,625 as DPI to oral doses of 50 mg/kg/day was non-inferior in clearing Mtb from the lungs of infected mice. We concluded that adjunct therapy with inhaled second-line agents has the potential to reduce the efficacious oral dose.

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAdministration, InhalationAnimalsAntitubercular AgentsDrug TaperingMiceNitroimidazolesOxazinesPharmaceutical PreparationsPowdersAntitubercular AgentsNitroimidazolesOxazinesPharmaceutical PreparationsPowdersTBA-354dry powder inhalationmultidrug resistanceMycobacterium tuberculosissutezolid TBA-354

Identifiers

PMID37291443
OpenAlexW4379792275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.